I attended a very interesting webinar today entitled, Combating Alert Fatigue: New Best Practices, put on by the folks at Wolters Kluwer Health / Medi-Span / Lexicomp / Dr. Howard Strasberg. As the title suggests the premise was to go over “best practices” for managing all of the alerts that are being triggered on drugs and continuously flashed in front of docs, pharmacists, and other key stakeholders that are making important prescribing decisions.

I certainly agree that there is an overwhelming number of alerts. And I agree that there needs to be processes in place by institutions to ensure that they are being seen.

 

Related Read: Help! There are too manyFDA Label Changes and Boxed Warnings and I Don't Know Which Ones to Pay Attention To!

 

However, I challenge data providers and alert creators to take it upon themselves, and not pass the buck to their end users, to ensure the data they are curating and presenting is more than just data. It needs to be actionable.

Using our own RxSuite® of analytics as an example, when a RxSignal® is triggered alerting to the fact that the FDA is likely to issue a Medwatch alert on a drug in the near future, we couple that alert with the ability to view medications that are in the same class, or line of treatment that have a more favorable post-marketing safety profile using our proprietary RxScore®.

Using the two analytics together provide an actionable alert that can be immediately used. This eliminates the concept of alert fatigue and creates data driven best practices.

Learn more about the RxSuite®

 

 Free Published Research Download - AdverseEvents Explorer



Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Topics: Evidex

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.